Biotech

Nuvation Bio Inc. conducted its first quarter 2026 earnings call on May 4, 2026. The company reviewed financial results for the period ending March 31, 2026, and provided a business update. Executives including CEO David Hung participated in the discussion.

24. April 2026 Von KI berichtet

Isomorphic Labs, a spinoff of Google DeepMind, announced that its AI-designed drugs are progressing to human trials. President Max Jaderberg shared the news at WIRED Health in London, highlighting a “broad and exciting pipeline of new medicines.” The development builds on DeepMind’s AlphaFold platform.

Scientists have created a new therapy combining LED technology and nanomaterials to eliminate cancer cells through localized heat, avoiding damage to healthy tissue. This approach aims to provide a safer alternative to traditional chemotherapy and radiotherapy.

27. Oktober 2025 Von KI berichtet

Dimitri Semenikhin, the retail trader who sparked the recent Beyond Meat stock rally, has announced a new investment in ETHZilla Corporation. The company, formerly a biotech firm known as 180 Life Sciences, recently pivoted to a digital asset treasury focused on ethereum. ETHZilla's shares surged following Semenikhin's disclosure, amid a broader trend of companies adopting crypto treasuries in 2025.

Biotech company Summit announced promising results from its lung cancer drug in recent trials. The drug demonstrated potential efficacy in treating advanced cases, marking a step forward in oncology treatments. Further studies are planned to confirm these findings.

9. September 2025 Von KI berichtet

Advancements in regenerative medicine, including 3D-printed spinal cord repairs, were announced on September 5. The technology aims to restore function in spinal injury patients.